MeiraGTx Holdings PLC (MGTX)

NASDAQ: MGTX · IEX Real-Time Price · USD
17.28 -1.22 (-6.57%)
Jan 18, 2022 2:49 PM EST - Market open
Market Cap767.85M
Revenue (ttm)n/a
Net Income (ttm)-80.11M
Shares Out44.45M
EPS (ttm)-1.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume140,439
Open18.02
Previous Close18.49
Day's Range17.22 - 18.40
52-Week Range11.60 - 24.90
Beta1.60
AnalystsStrong Buy
Price Target36.57 (+111.7%)
Earnings DateNov 11, 2021

About MGTX

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentos...

IndustryBiotechnology
Founded2015
CEOAlexandria Forbes
Employees271
Stock ExchangeNASDAQ
Ticker SymbolMGTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for MGTX stock is "Strong Buy." The 12-month stock price forecast is 36.57, which is an increase of 111.69% from the latest price.

Price Target
$36.57
(111.69% upside)
Analyst Consensus: Strong Buy

News

MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation

LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and con...

1 month ago - GlobeNewsWire

MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom

MeiraGTx Holdings plc (NASDAQ: MGTX) has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX). Xerostomia, or Dry mouth, happens ...

1 month ago - Benzinga

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of ...

LONDON and NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive preliminary data from ...

1 month ago - GlobeNewsWire

MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regu...

LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call ...

1 month ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -13.46% and 38.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

MeiraGTx Reports Third Quarter 2021 Financial and Operational Results

LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third...

2 months ago - GlobeNewsWire

MeiraGTx to Participate in Upcoming Virtual Investor Conferences

LONDON and NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., P...

2 months ago - GlobeNewsWire

Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q3 Earnings Expected to Decline

MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference

LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D.,...

3 months ago - GlobeNewsWire

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Other symbols:QURESLDBSRPTVYGR
4 months ago - Zacks Investment Research

MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Trea...

LONDON and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced new data from subjects treated...

4 months ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 13.21% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

MeiraGTx Reports Second Quarter 2021 Financial and Operational Results

LONDON and NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the secon...

5 months ago - GlobeNewsWire

MeiraGTx Holdings PLC (MGTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Tops Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -25.58% and 83.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

MeiraGTx Announces Participation at Upcoming Investor Conferences

LONDON and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., p...

8 months ago - GlobeNewsWire

MeiraGTx (MGTX) Sees Hammer Chart Pattern: Time to Buy?

MeiraGTx Holdings (MGTX) has been struggling lately, but the selling pressure may be coming to an end soon

8 months ago - Zacks Investment Research

MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit

LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D.,...

8 months ago - GlobeNewsWire

MeiraGTx to Present at the 2021 Barclays Global Healthcare Conference

LONDON and NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D.,...

10 months ago - GlobeNewsWire

Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to Decline

MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide

NEW YORK and BEIJING, Feb. 23, 2021 /PRNewswire/ -- Graviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. Samuel Waksal, and Beijing Tide Pha...

Other symbols:KDMN
10 months ago - PRNewsWire

MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia

Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET

1 year ago - GlobeNewsWire

MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., ...

1 year ago - GlobeNewsWire

MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., ...

1 year ago - GlobeNewsWire

Why MeiraGTx Holdings Stock Is Down Today

The company announced the pricing of a public offering of common stock.

1 year ago - The Motley Fool